79 results
ARS
2023 FY
CRBU
Caribou Biosciences Inc
25 Apr 24
Annual report to shareholders
4:06pm
product candidates cause serious adverse events or undesirable side effects, including injury and death, or have other properties that could delay … CAR- T cell therapy with programmed cell death protein 1 (“PD-1”) removed from the CAR-T cell surface by a genome-edited knockout of the PDCD1 gene. We
DEFA14A
CRBU
Caribou Biosciences Inc
25 Apr 24
Additional proxy soliciting materials
4:04pm
the Company’s 2027 annual meeting of stockholders and until their respective successors are duly elected and qualified or until their earlier death
424B5
wfvpb
14 Jul 23
Prospectus supplement for primary offering
5:31pm
424B5
diq8ro
13 Jul 23
Prospectus supplement for primary offering
4:56pm
8-K
EX-99.2
8xu56ag
13 Jul 23
Caribou Biosciences Reports Positive Clinical Data from Dose Escalation of CB-010 ANTLER Phase 1 Trial in r/r B-NHL
4:23pm
8-K
g047i
16 Jun 23
Submission of Matters to a Vote of Security Holders
4:05pm
ARS
n66lpqdtu4imz7bm2c8x
28 Apr 23
Annual report to shareholders
12:00am
8-K/A
2hu0kcl48x
22 Sep 22
Submission of Matters to a Vote of Security Holders
6:42pm
8-K
ytzwm1i 60vowvc0b6u
22 Sep 22
Submission of Matters to a Vote of Security Holders
4:05pm
DEF 14A
3i2hegdv
11 Aug 22
Definitive proxy
4:04pm